| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma KI Kollaborációs, BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, ... N Engl J Med 380 (12), 1116-1127, 2019 | 2792* | 2019 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1578 | 2012 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 2019 | 1515 | 2019 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 942 | 2017 |
| Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. BIGC Group, H Mouridsen, A Giobbie-Hurder, A Goldhirsch, B Thürlimann, ... N Engl J Med 361 (8), 766-776, 2009 | 613* | 2009 |
| Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical … Regan, MM, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ... Lancet Oncol 12 (12), 1101-1108, 2011 | 465 | 2011 |
| Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … C investigators, JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, ... Lancet Oncology 22 (1), 51-65, 2021 | 423 | 2021 |
| Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International … Viale, G, A Giobbie-Hurder, MM Regan, AS Coates, MG Mastropasqua, ... J Clin Oncol 26 (34), 5569-5575, 2008 | 401 | 2008 |
| Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 IBCS Group, O Pagani, S Gelber, K Price, D Zahrieh, R Gelber, ... Ann Oncol 15 (12), 1749-1759, 2004 | 115 | 2004 |
| Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil E Hitre, B Budai, V Adleff, F Czegledi, Z Horvath, F Gyergyay, J Lövey, ... Pharmacogenetics and genomics 15 (10), 723-730, 2005 | 95 | 2005 |
| Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for … MM Regan, KN Price, A Giobbie-Hurder, B Thürlimann, RD Gelber, ... Breast Cancer Res 13 (2), 209, 2011 | 94 | 2011 |
| Recent advances in the neoadjuvant treatment of breast cancer G Rubovszky, Z Horváth Journal of Breast Cancer 20 (2), 119, 2017 | 75 | 2017 |
| MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or … E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ... Journal of Clinical Oncology 34 (15_suppl), 4007-4007, 2016 | 69 | 2016 |
| Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study G Rubovszky, I Láng, E Ganofszky, Z Horváth, E Juhos, T Nagy, E Szabó, ... European Journal of Cancer 49 (18), 3806-3812, 2013 | 55 | 2013 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 45 | 2021 |
| Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. P Merle, JF Blanc, JM Phelip, G Pelletier, JP Bronowicki, Y Touchefeu, ... Lancet Gastroenterol Hepatol 4 (6), 454-465, 2019 | 45 | 2019 |
| Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer. LJ Wirth, E Eigendorff, J Capdevila, LG Paz-Ares, CC Lin, MH Taylor, ... Journal of Clinical Oncology 36 (15_suppl), 6024-6024, 2018 | 44 | 2018 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 40 | 2023 |
| Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma … E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ... Journal of Clinical Oncology 34 (4_suppl), 193-193, 2016 | 38 | 2016 |
| Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine … A Giobbie-Hurder, KN Price, RD Gelber, CIBCSG BIG Clinical trials 6 (3), 272-278, 2009 | 36 | 2009 |
Gábor Rubovszkymedical oncologist, National Institute of Oncology, Budapest, HungaryVerified email at oncol.hu
